Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.35 |
| ▸ | F11 | P03951 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19065464 | 1.00 | NPY5R (0.39) | NPY5RSCN2ADGAT1F11KLKB1 | |
| Trifluoroacetic Acid SCHEMBL19065608 | 0.97 | NPY5R (0.38) | NPY5RSCN2ADGAT1F11KLKB1 | |
| Trifluoroacetic Acid SCHEMBL29675366 | 0.97 | NPY5R (0.38) | NPY5RSCN2ADGAT1F11KLKB1 | |
| SCHEMBL19065243 | 0.93 | NPY5R (0.45) | NPY5RSCN2AHPGDSEGFRSSTR3 | |
| SCHEMBL19065253 | 0.89 | NPY5R (0.44) | NPY5RSCN2AHPGDSEGFRSSTR3 | |
| Trifluoroacetic Acid SCHEMBL29675397 | 0.88 | NPY5R (0.41) | NPY5RSCN2ADGAT1HPGDSMET | |
| Trifluoroacetic Acid SCHEMBL19065563 | 0.88 | NPY5R (0.41) | NPY5RSCN2ADGAT1HPGDSMET | |
| Trifluoroacetic Acid SCHEMBL29675591 | 0.87 | NPY5R (0.40) | NPY5RSCN2ADGAT1HPGDS | |
| Trifluoroacetic Acid SCHEMBL19065703 | 0.87 | NPY5R (0.40) | NPY5RSCN2ADGAT1HPGDS | |
| Trifluoroacetic Acid SCHEMBL19065542 | 0.84 | NPY5R (0.44) | NPY5RSCN2ADGAT1HPGDSMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885SCN2A 1369/4885DGAT1 3641/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885SCN2A 1369/4885DGAT1 3641/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885SCN2A 1369/4885DGAT1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.